未经证实:蒽环类化疗药物可对乳腺癌患者产生心脏毒性,导致心肌细胞死亡和纤维化,进一步发展为心力衰竭。然而,蒽环类化疗后的乳腺癌患者心肌微循环状况未知。因此,使用体素内不相干运动(IVIM)成像非侵入性观察蒽环类化疗后乳腺癌患者的心肌微循环状况。
未经批准:报告一名43岁女性患者,患有右乳肿块。术前超声引导下穿刺活检显示右乳腺浸润性癌伴纤维腺瘤。对右侧乳腺癌行前哨淋巴结活检联合简化根治术。术后病理报告乳腺癌(pT2N2M0IIIA)。患者接受了八次EC-TH化疗方案,前四届会议和后四届会议都采用了EC和TH方案,分别。化疗期间,在此期间发生了II级骨髓抑制,胸部CT和腹部CT显示无转移,心电图和心脏超声报告恢复正常。在第一次化疗开始时(基线)和第三次化疗后进行心脏电影磁共振和IVIM成像,第五,第八次化疗,分别。我们发现,快速表观扩散系数(ADCfast)和f参数似乎显示出从基线到第五次化疗的下降趋势,其中IVIMfast值从163×10-3mm2/s下降到148×10-3mm2/s,最后下降到134×10-3mm2/s,f值从45%下降到36%,然后下降到30%,分别。ADCfast和f值显示第五和第八次化疗的倾向。
UNASSIGNED:我们的病例报告显示,IVIM技术可能可以在蒽环类化疗后早期定量检测乳腺癌患者的无创心肌微循环。也就是说,IVIM技术对乳腺癌患者蒽环类药物化疗后的心血管风险监测和心肌微循环的预后评估有一定的帮助。
UNASSIGNED: Anthracycline chemotherapy drugs can produce cardiotoxicity in patients with breast cancer, leading to myocardial cell death and fibrosis, further developing into cardiac failure. However, the condition of myocardial microcirculation was unknown in breast cancer after
anthracycline chemotherapy. As a result, intravoxel incoherent motion (IVIM) imaging was used to non-invasively observe the condition of myocardial microcirculation in a patient with breast cancer after anthracycline chemotherapy.
UNASSIGNED: A 43-year-old female patient with a right breast lump was reported. Preoperative ultrasound-guided needle biopsy showed invasive carcinoma of the right breast with fibroadenoma. Sentinel lymph node biopsy combined with simplified radical surgery for right breast cancer was performed. Postoperative pathological findings reported breast cancer (pT2N2M0 IIIA). The patient underwent eight sessions of the EC-TH chemotherapy scheme, and the EC and the TH schemes were adopted for the first four sessions and the last four sessions, respectively. During chemotherapy, during which there was the occurrence of Grade II myelosuppression, chest CT and abdomen CT showed no metastasis, and ECG and cardiac ultrasound
reports returned to normal. Cardiac cine magnetic resonance and IVIM imaging were performed at the beginning of the first chemotherapy session (baseline) and after the third, fifth, and eighth chemotherapy sessions, respectively. We found that the fast apparent diffusion coefficient (ADCfast) and f parameters appeared to show a downward trend from the baseline to the fifth chemotherapy session, where the IVIMfast values declined from 163 × 10-3 mm2/s to 148 × 10-3 mm2/s and finally to 134 × 10-3 mm2/s and f values declined from 45% to 36% and then to 30%, respectively. ADCfast and f values showed an inclination from the fifth and eighth chemotherapy sessions.
UNASSIGNED: Our
case report showed that IVIM technology can likely detect non-invasive myocardial microcirculation early and quantitatively after
anthracycline chemotherapy in patients with breast cancer. That is, IVIM technology seems to be helpful for cardiovascular risk monitoring and prognosis assessment of myocardial microcirculation in patients with breast cancer after anthracycline chemotherapy.